glp1versus

Bydureon BCise vs Rybelsus

exenatide extended-release (GLP-1 receptor agonist) vs semaglutide (GLP-1 receptor agonist) — a complete side-by-side comparison.

AstraZenecaNovo Nordisk

Bydureon BCise weight loss

2.3%

Rybelsus weight loss

4.4%

Bydureon BCise dosing

Once weekly

Rybelsus dosing

Once daily

Reviewed by Dr. Elena Vance, DOLast reviewed 11 sources cited

Quick Summary

Bydureon BCise (exenatide) and Rybelsus (semaglutide) are both glp-1 receptor agonists. In clinical trials, Rybelsus showed greater weight loss (4.4% vs 2.3%).

See the comparison table below for detailed side-by-side data.

Bydureon BCise vs Rybelsus: Full Comparison

FeatureBydureon BCise(exenatide extended-release)Rybelsus(semaglutide)
Active Ingredientexenatidesemaglutide
Drug ClassGLP-1 receptor agonistGLP-1 receptor agonist
ManufacturerAstraZenecaNovo Nordisk
FDA Approved2012-01-272019-09-20
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
Routesubcutaneous injectionoral
FrequencyOnce weeklyOnce daily
Starting Dose2 mg weekly3 mg daily
Maintenance Dose2 mg weekly7 mg or 14 mg daily
Max Dose2 mg weekly14 mg daily
Weight Loss (%)2.3%4.4%
A1C Reduction1.3%1.4%
Key TrialDURATION-1 (30 weeks)PIONEER 1 (26 weeks)
List Price$800-$950/month$935-$1,029/month
With Insurance$25-$100/month (varies by plan)$25-$150/month (varies by plan)
Savings CardLimited savings programs available$10/month (Novo Nordisk savings card, commercially insured)

Side Effects: Bydureon BCise vs Rybelsus

Side EffectBydureon BCiseRybelsus
Nausea11%11-20%
Diarrhea9%5-10%
Injection site nodule10-17%Not reported
Headache8%Not reported
Vomiting4%4-8%
Constipation6%3-5%
Pancreatitis (rare)<1%<0.5%
Abdominal painNot reported5-11%
Decreased appetiteNot reported3-9%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Bydureon BCise vs OzempicRybelsus vs OzempicBydureon BCise vs WegovyRybelsus vs WegovyBydureon BCise vs MounjaroRybelsus vs MounjaroBydureon BCise vs ZepboundRybelsus vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Bydureon BCise FDA Drugs@FDA approval record — FDA
  2. Rybelsus FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. DURATION-1 clinical trial record — ClinicalTrials.gov
  2. PIONEER 1 clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Drucker DJ et al. Exenatide once weekly versus twice daily for treatment of type 2 diabetes (DURATION-1). Lancet 2008;372:1240-1250 — The Lancet
  2. Aroda VR et al. PIONEER 1: Oral Semaglutide Monotherapy vs Placebo in Type 2 Diabetes. Diabetes Care 2019;42:1724-1732 — Diabetes Care
  3. Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med 2019;381:841-851 — New England Journal of Medicine

Manufacturer Information

  1. Bydureon BCise patient website (AstraZeneca) — AstraZeneca
  2. Rybelsus patient and healthcare provider website — Novo Nordisk

Reference Entries

  1. Exenatide entry on Wikipedia — Wikipedia
  2. Semaglutide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.